Z17.22

Clinical Causes: Genetic mutations in breast tissue cells that lead to the loss of progesterone receptors. Biological changes within the tumor as it progresses, causing receptor loss. Previous exposure to certain hormonal therapies or treatments that might influence receptor status. Differences in tumor biology, including variations in receptor expression that are innate to the tumor.

Key Symptoms: Typically, there are no specific symptoms directly caused by PR-negative status itself, as it is a characteristic of the tumor. Symptoms associated with breast cancer may include a lump in the breast, changes in breast size or shape, skin changes over the breast, nipple discharge, or pain.

Diagnosis Path: Diagnosing progesterone receptor status involves examining tumor tissue obtained through a biopsy. The tissue is tested using immunohistochemistry (IHC) to determine the presence or absence of hormone receptors. A positive status indicates the presence of progesterone receptors, whereas a negative status, as indicated by Z17.22, means none are detected. Receptor testing is a standard part of breast cancer diagnostics, guiding treatment options and prognosis.

Treatment Protocols: While the specific treatment plan depends on the overall clinical picture, including tumor size and other factors, PR-negative tumors often do not respond to hormonal therapies like progesterone or anti-progesterone drugs. Treatment strategies may include: - Surgery to remove the tumor or breast tissue. - Chemotherapy to target cancer cells. - Targeted therapies if specific molecular markers are present. - Radiation therapy to eliminate residual cancer cells post-surgery. Treatment decisions are made by a healthcare team considering all aspects of the patient’s condition.